Navigation Links
Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
Date:5/3/2011

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that several members of management will speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing.  The conference is taking place May 8-11, 2011 at the Toronto Convention Center.  

  • James Levine, President and Chief Executive Officer, will make opening remarks at a plenary breakfast, What Consumers and Manufacturers Need from Industrial Biotech Companies: A Customer Perspective on Tuesday, May 10th at 7:00 am.
  • Janet Roemer, Chief Operating Officer, will be moderating a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, on Wednesday, May 11th at 11:00 am. Roemer will also be speaking on a panel, The Power of Enzymes, Tuesday, May 10th at 3:00 pm
  • Ken Barrett, Vice President, Business Development, will be moderating a panel, Protein Engineering and Screening Methods, Tuesday, May 10th at 9:00 am.
  • David Weiner, Ph.D., Vice President, R&D Strategy and Partnerships, will be speaking on a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, Wednesday, May 11th at 11:00 am.

  • The Company will also have a booth at space 316 in the Toronto Convention Center.

    For more information on the BIO Industrial Biotechnology Conference please visit http://www.bio.org/worldcongress/index.asp

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

    Vice President, Corporate Communications

    858-431-8580

    kelly.lindenboom@verenium.com

    Sarah Carmody

    Manager, Corporate Communications

    858-431-8581

    sarah.carmody@verenium.com
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/23/2017)... ... August 23, 2017 , ... ... announced orders for advanced VPG+ 800 Volume Pattern Generators from two major Asian ... tomorrow’s demand for production of advanced photomasks as well as a solution for ...
    (Date:8/22/2017)... ... August 22, 2017 , ... ... built upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox has adapted their ... pipeline to be provide scientists with easy to understand reports, extended indel analysis, ...
    (Date:8/21/2017)... ... August 21, 2017 , ... ... its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ ... In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on ...
    (Date:8/17/2017)... ... August 17, 2017 , ... CNA Finance Chief ... provided a research update on Aytu Bioscience and cited promising increases in the ... Soulstring, prescription rates for Natesto® have more than doubled since March of this ...
    Breaking Biology Technology:
    (Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
    (Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
    (Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
    Breaking Biology News(10 mins):